

11

12

13

14

15

16

17

18

19

20

21

Article

Constructing artificial features with Grammatical Evolution for the motor symptoms of Parkinson's Disease

Aimilios Psathas¹, Ioannis G. Tsoulos²,*, Alexandros Tzallas³ and Vasileios Charilogis⁴

- Department of Informatics and Telecommunications, University of Ioannina, Greece; pint00141@uoi.gr
- ² Department of Informatics and Telecommunications, University of Ioannina, Greece; itsoulos@uoi.gr
- ³ Department of Informatics and Telecommunications, University of Ioannina, Greece; tzallas@uoi.gr
- Department of Informatics and Telecommunications, University of Ioannina, Greece; v.charilog@uoi.gr
- * Correspondence: itsoulos@uoi.gr

Abstract: This study introduces a set of features designed to capture the motor symptoms of Parkinson's Disease (PD) through detailed motion analysis, with a specific focus on how these symptoms change before and after medication. The features reflect key aspects of patient movement, such as tremor intensity, slowness, rigidity, instability, and irregularity in motion patterns. By quantifying how consistently and smoothly a patient performs specific tasks, the features provide insight into motor control quality and neurological function. Crucially, they are labeled according to the patient's state-before and after receiving medication—allowing for a clear comparison of treatment effects. This enables not only objective tracking of symptom severity, but also evaluation of medication responsiveness. These features address a fundamental clinical need: moving beyond subjective observation toward continuous, data-driven monitoring of disease progression and therapeutic effectiveness in Parkinson's Disease. In the current work the impact of feature construction using Grammatical Evolution on previously mentioned features in evaluated. We compare traditional neural architectures (MLP with ADAM, MLP with Genetic Algorithm, and RBF networks) against models trained on artificially constructed features. The results demonstrate a substantial reduction in classification error when 2 to 5 constructed features are used, achieving the lowest error rate (14.33%) with four generated features (FC4GEN), compared to 38.65% for the best baseline model (RBF). These findings highlight the effectiveness of evolutionary feature construction in enhancing classification accuracy.

Keywords: Machine learning; Evolutionary algorithms; Genetic Programming; Grammatical Evolution

Received: Revised: Accepted: Published:

Citation: Psathas, A.; Tsoulos, I.G.; Tzallas, A.; Charilogis, V. . Constructing artificial features with Grammatical Evolution for the motor symptoms of Parkinson's Disease. *Journal Not Specified* **2025**, 1, 0. https://doi.org/

Copyright: © 2025 by the authors. Submitted to *Journal Not Specified* for possible open access publication under the terms and conditions of the Creative Commons Attri-bution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

- 1. Introduction
- 2. Materials and Methods
- 3. Results

4. Conclusions

Author Contributions: For research articles with several authors, a short paragraph specifying their individual contributions must be provided. The following statements should be used "Conceptualization, X.X. and Y.Y.; methodology, X.X.; software, X.X.; validation, X.X., Y.Y. and Z.Z.; formal analysis, X.X.; investigation, X.X.; resources, X.X.; data curation, X.X.; writing—original draft preparation, X.X.; writing—review and editing, X.X.; visualization, X.X.; supervision, X.X.; project administration, X.X.; funding acquisition, Y.Y. All authors have read and agreed to the published version of the manuscript.", please turn to the CRediT taxonomyfor the term explanation. Authorship must be limited to those who have contributed substantially to the work reported.

Funding: Please add: "This research received no external funding" or "This research was funded by NAME OF FUNDER grant number XXX." and and "The APC was funded by XXX". Check carefully that the details given are accurate and use the standard spelling of funding agency names at https://search.crossref.org/funding, any errors may affect your future funding.

Institutional Review Board Statement: In this section, you should add the Institutional Review Board Statement and approval number, if relevant to your study. You might choose to exclude this statement if the study did not require ethical approval. Please note that the Editorial Office might ask you for further information. Please add "The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of NAME OF INSTITUTE (protocol code XXX and date of approval)." for studies involving humans. OR "The animal study protocol was approved by the Institutional Review Board (or Ethics Committee) of NAME OF INSTITUTE (protocol code XXX and date of approval)." for studies involving animals. OR "Ethical review and approval were waived for this study due to REASON (please provide a detailed justification)." OR "Not applicable" for studies not involving humans or animals.

Informed Consent Statement: Any research article describing a study involving humans should contain this statement. Please add "Informed consent was obtained from all subjects involved in the study." OR "Patient consent was waived due to REASON (please provide a detailed justification)." OR "Not applicable" for studies not involving humans. You might also choose to exclude this statement if the study did not involve humans. Written informed consent for publication must be obtained from participating patients who can be identified (including by the patients themselves). Please state "Written informed consent has been obtained from the patient(s) to publish this paper" if applicable.

Data Availability Statement: We encourage all authors of articles published in MDPI journals to share their research data. In this section, please provide details regarding where data supporting reported results can be found, including links to publicly archived datasets analyzed or generated during the study. Where no new data were created, or where data is unavailable due to privacy or ethical re-strictions, a statement is still required. Suggested Data Availability Statements are available in section "MDPI Research Data Policies" at https://www.mdpi.com/ethics.

Acknowledgments: In this section you can acknowledge any support given which is not covered by the author contribution or funding sections. This may include administrative and technical support, or donations in kind (e.g., materials used for experiments). Where GenAI has been used for purposes such as generating text, data, or graphics, or for study design, data collection, analysis, or interpretation of data, please add "During the preparation of this manuscript/study, the author(s) used [tool name, version information] for the purposes of [description of use]. The authors have reviewed and edited the output and take full responsibility for the content of this publication."

Conflicts of Interest: Declare conflicts of interest or state "The authors declare no conflicts of interest." Authors must identify and declare any personal circumstances or interest that may be perceived as

74

82

83

87

inappropriately influencing the representation or interpretation of reported research results. Any role of the funders in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript; or in the decision to publish the results must be declared in this section. If there is no role, please state "The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results".

References

- 1. Author 1, T. The title of the cited article. *Journal Abbreviation* **2008**, 10, 142–149.
- 2. Author 2, L. The title of the cited contribution. In *The Book Title*; Editor1, F., Editor2, A., Eds.; Publishing House: City, Country, 2007; pp. 32–58.
- 3. Author 1, A.; Author 2, B. Book Title, 3rd ed.; Publisher: Publisher Location, Country, 2008; pp. 154–196.
- 4. Author 1, A.B.; Author 2, C. Title of Unpublished Work. *Abbreviated Journal Name* year, phrase indicating stage of publication (submitted; accepted; in press).
- 5. Title of Site. Available online: URL (accessed on Day Month Year).
- 6. Author 1, A.B.; Author 2, C.D.; Author 3, E.F. Title of presentation. In Proceedings of the Name of the Conference, Location of Conference, Country, Date of Conference (Day Month Year); Abstract Number (optional), Pagination (optional).
- 7. Author 1, A.B. Title of Thesis. Level of Thesis, Degree-Granting University, Location of University, Date of Completion.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.